First Time Loading...

Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 14.4 USD 4.2% Market Closed
Updated: May 2, 2024

Urogen Pharma Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Urogen Pharma Ltd
Operating Income Peer Comparison

Comparables:
CLGN
KMDA
B
BLRX
ENTX
B
BONS

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Operating Income
-$65.5m
CAGR 3-Years
20%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Operating Income
-$6.6m
CAGR 3-Years
-6%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Operating Income
$10.1m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
11%
B
BioLine RX Ltd
TASE:BLRX
Operating Income
-$43m
CAGR 3-Years
-23%
CAGR 5-Years
-11%
CAGR 10-Years
-10%
Entera Bio Ltd
NASDAQ:ENTX
Operating Income
-$8.9m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Operating Income
-₪32.9m
CAGR 3-Years
-22%
CAGR 5-Years
-14%
CAGR 10-Years
-13%

See Also

What is Urogen Pharma Ltd's Operating Income?
Operating Income
-65.5m USD

Based on the financial report for Dec 31, 2023, Urogen Pharma Ltd's Operating Income amounts to -65.5m USD.

What is Urogen Pharma Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
3%

Over the last year, the Operating Income growth was 17%. The average annual Operating Income growth rates for Urogen Pharma Ltd have been 20% over the past three years , 3% over the past five years .